Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 7Cyclophosphamide 7Whole-Body Irradiation 6Busulfan 6Mycophenolic Acid 5fludarabine 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Azacitidine 4venetoclax 3Tacrolimus 3Cyclosporine 3Biopsy 3Vorinostat 2Specimen Handling 2Rituximab 2Methotrexate 2Etoposide 2Cytarabine 2Clofarabine 2Antilymphocyte Serum 2thymoglobulin 1pegylated granulocyte colony-stimulating factor 1merphos 1ivosidenib 1decitabine and cedazuridine drug combination 1cedazuridine 1Thiotepa 1TAK-243 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × cedazuridine × 90 days × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡